Thermo Fisher Scientific Inc. (TMO) Income Statement Analysis

See more : LIWANLI Innovation Co., Ltd. (3054.TW) Income Statement Analysis – Financial Results

Complete financial analysis of Thermo Fisher Scientific Inc. (TMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Thermo Fisher Scientific Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Thermo Fisher Scientific Inc. (TMO)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.thermofisher.com

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	42.86B	44.92B	39.21B	32.22B	25.54B	24.36B	20.92B	18.27B	16.97B	16.89B	13.09B	12.51B	11.73B	10.79B	10.11B	10.50B	9.75B	3.79B	2.63B	2.21B	2.10B	2.09B	2.19B	2.28B	2.47B	3.87B	3.56B	2.93B	2.21B	1.59B	1.25B	949.00M	805.50M	708.00M	579.00M	500.60M	383.40M	331.60M	265.70M
Cost of Revenue	25.74B	25.42B	18.98B	15.71B	13.72B	12.99B	10.96B	9.46B	8.78B	8.97B	7.34B	6.99B	6.74B	6.22B	5.96B	6.29B	5.94B	2.22B	1.44B	1.19B	1.15B	1.16B	1.23B	1.26B	1.26B	2.02B	1.84B	1.54B	1.12B	866.30M	713.10M	579.80M	510.20M	443.00M	384.10M	325.70M	248.70M	219.30M	174.30M
Gross Profit	17.11B	19.50B	20.23B	16.51B	11.83B	11.36B	9.96B	8.82B	8.18B	7.92B	5.75B	5.52B	4.99B	4.57B	4.15B	4.21B	3.80B	1.57B	1.19B	1.01B	948.02M	927.38M	958.62M	1.02B	1.21B	1.84B	1.72B	1.39B	1.08B	719.00M	536.60M	369.20M	295.30M	265.00M	194.90M	174.90M	134.70M	112.30M	91.40M
Gross Profit Ratio	39.93%	43.42%	51.60%	51.23%	46.30%	46.65%	47.60%	48.24%	48.23%	46.89%	43.93%	44.10%	42.54%	42.39%	41.04%	40.07%	39.03%	41.36%	45.38%	45.99%	45.21%	44.45%	43.81%	44.81%	48.81%	47.65%	48.36%	47.40%	49.05%	45.35%	42.94%	38.90%	36.66%	37.43%	33.66%	34.94%	35.13%	33.87%	34.40%
Research & Development	1.34B	1.47B	1.41B	1.18B	1.00B	967.00M	888.00M	754.80M	692.30M	691.10M	395.50M	376.40M	340.60M	287.20M	246.10M	249.10M	238.70M	170.18M	152.78M	134.68M	146.39M	155.12M	171.61M	176.76M	171.10M	367.30M	337.30M	0.00	269.60M	103.70M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	8.45B	7.13B	6.84B	5.76B	4.93B	4.82B	4.41B	4.04B	3.72B	3.99B	2.91B	2.83B	2.65B	2.39B	2.20B	2.69B	2.55B	1.11B	761.79M	626.46M	568.14M	564.66M	620.10M	646.92M	673.00M	937.60M	840.70M	990.70M	480.80M	373.20M	370.60M	271.70M	233.60M	210.60M	164.40M	144.60M	117.10M	91.60M	78.70M
Other Expenses	536.00M	2.40B	1.76B	1.67B	1.71B	9.00M	-28.00M	-4.10M	-15.50M	16.40M	-56.00M	3.70M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	113.60M	162.30M	135.70M	115.20M	85.00M	62.30M	42.40M	29.20M	23.40M	18.80M	12.70M	11.10M	10.10M	8.40M	7.80M
Operating Expenses	10.24B	10.99B	10.01B	8.61B	7.65B	7.53B	6.89B	6.18B	5.73B	6.01B	4.06B	3.95B	3.64B	3.25B	3.04B	2.94B	2.79B	1.28B	914.56M	761.14M	714.53M	719.78M	791.72M	823.68M	957.70M	1.47B	1.31B	1.11B	835.40M	539.20M	413.00M	300.90M	257.00M	229.40M	177.10M	155.70M	127.20M	100.00M	86.50M
Cost & Expenses	36.00B	36.41B	28.99B	24.33B	21.36B	20.53B	17.85B	15.64B	14.51B	14.98B	11.40B	10.95B	10.38B	9.46B	9.00B	9.23B	8.73B	3.50B	2.35B	1.95B	1.86B	1.88B	2.02B	2.08B	2.22B	3.49B	3.15B	2.65B	1.96B	1.41B	1.13B	880.70M	767.20M	672.40M	561.20M	481.40M	375.90M	319.30M	260.80M
Interest Income	879.00M	272.00M	43.00M	65.00M	224.00M	137.00M	81.00M	48.40M	30.60M	47.70M	28.00M	25.20M	26.90M	12.50M	16.10M	51.70M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.38B	726.00M	536.00M	553.00M	676.00M	667.00M	592.00M	469.60M	414.90M	479.90M	262.10M	241.60M	175.30M	84.70M	118.10M	151.50M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.41B	3.38B	2.59B	2.33B	2.28B	2.27B	2.03B	1.76B	1.69B	1.68B	999.90M	983.70M	863.50M	770.00M	787.30M	792.70M	756.80M	240.77M	123.27M	66.14M	58.55M	56.38M	98.52M	97.49M	113.60M	162.30M	135.70M	115.20M	85.00M	62.30M	42.40M	29.20M	23.40M	18.80M	12.70M	11.10M	10.10M	8.40M	7.80M
EBITDA	11.20B	11.94B	12.96B	10.19B	6.46B	6.20B	5.25B	4.25B	4.04B	4.25B	2.58B	2.49B	2.18B	1.91B	1.83B	2.07B	1.78B	502.07M	435.89M	336.34M	279.30M	193.08M	265.43M	295.65M	362.20M	353.40M	371.60M	399.40M	332.30M	242.10M	166.00M	97.50M	61.70M	54.40M	30.50M	30.30M	17.60M	20.70M	12.70M
EBITDA Ratio	26.12%	26.84%	31.03%	31.67%	25.88%	25.64%	24.62%	24.30%	24.49%	21.63%	20.31%	20.60%	19.07%	19.54%	18.92%	19.95%	18.65%	15.11%	14.55%	14.22%	14.63%	9.25%	16.53%	13.55%	23.20%	13.51%	12.97%	10.53%	9.21%	10.02%	12.68%	4.16%	0.30%	2.53%	-0.14%	1.96%	-1.85%	3.44%	0.45%
Operating Income	6.86B	8.39B	10.03B	7.79B	4.59B	3.78B	2.97B	2.45B	2.34B	2.50B	1.61B	1.48B	1.25B	1.26B	1.05B	1.23B	974.40M	241.96M	263.49M	237.51M	184.77M	155.45M	34.20M	198.16M	248.60M	375.80M	407.00M	284.20M	247.30M	179.80M	123.60M	68.30M	38.30M	35.60M	17.80M	19.20M	7.50M	12.30M	4.90M
Operating Income Ratio	16.00%	18.69%	25.57%	24.19%	17.99%	15.53%	14.19%	13.40%	13.77%	14.82%	12.30%	11.85%	10.62%	11.72%	10.38%	11.71%	10.00%	6.38%	10.01%	10.77%	8.81%	7.45%	1.56%	8.69%	10.06%	9.72%	11.44%	9.69%	11.20%	11.34%	9.89%	7.20%	4.75%	5.03%	3.07%	3.84%	1.96%	3.71%	1.84%
Total Other Income/Expenses	-561.00M	-558.00M	-1.19B	-567.00M	-524.00M	-521.00M	-531.00M	-434.10M	-399.60M	-415.80M	-290.10M	-212.70M	-112.40M	-100.30M	-121.80M	-79.80M	-93.10M	-32.59M	-7.88M	4.78M	35.25M	131.50M	42.32M	-23.90M	-230.10M	-28.30M	-100.30M	17.40M	-8.30M	-7.20M	-13.60M	19.80M	33.70M	15.40M	16.40M	8.20M	15.20M	4.90M	6.90M
Income Before Tax	6.30B	7.84B	8.84B	7.23B	4.07B	3.26B	2.43B	2.02B	1.94B	2.09B	1.32B	1.27B	1.13B	1.16B	927.10M	1.15B	881.30M	209.37M	285.90M	259.22M	218.63M	287.99M	76.52M	174.26M	18.50M	347.50M	414.00M	301.60M	239.00M	172.60M	110.00M	88.10M	72.00M	51.00M	34.20M	27.40M	22.70M	17.20M	11.80M
Income Before Tax Ratio	14.70%	17.44%	22.55%	22.43%	15.93%	13.39%	11.61%	11.08%	11.41%	12.36%	10.08%	10.15%	9.61%	10.79%	9.17%	10.95%	9.04%	5.52%	10.86%	11.75%	10.43%	13.80%	3.50%	7.64%	0.75%	8.98%	11.63%	10.28%	10.83%	10.89%	8.80%	9.28%	8.94%	7.20%	5.91%	5.47%	5.92%	5.19%	4.44%
Income Tax Expense	284.00M	703.00M	1.11B	850.00M	374.00M	324.00M	201.00M	-1.40M	-43.90M	191.70M	40.40M	11.00M	107.00M	131.50M	75.80M	160.90M	101.70M	43.05M	87.60M	40.85M	45.94M	92.99M	26.93M	112.22M	33.10M	170.70M	174.70M	110.80M	98.90M	69.20M	33.40M	27.50M	24.90M	17.10M	9.60M	7.30M	4.60M	2.90M	2.20M
Net Income	6.00B	6.95B	7.73B	6.38B	3.70B	2.94B	2.23B	2.02B	1.98B	1.89B	1.27B	1.18B	1.33B	1.04B	850.30M	994.20M	761.10M	168.94M	223.22M	361.84M	200.01M	309.73M	-781.00K	-36.11M	-174.60M	181.90M	239.30M	190.80M	140.10M	103.40M	76.60M	59.20M	47.10M	33.90M	24.60M	20.10M	18.10M	14.30M	9.60M
Net Income Ratio	13.99%	15.47%	19.70%	19.79%	14.47%	12.06%	10.64%	11.06%	11.64%	11.22%	9.73%	9.42%	11.34%	9.60%	8.41%	9.47%	7.81%	4.46%	8.48%	16.40%	9.54%	14.85%	-0.04%	-1.58%	-7.07%	4.70%	6.73%	6.51%	6.35%	6.52%	6.13%	6.24%	5.85%	4.79%	4.25%	4.02%	4.72%	4.31%	3.61%
EPS	15.53	17.73	19.61	16.10	9.24	7.31	5.64	5.12	4.96	4.76	3.53	3.24	3.49	2.57	2.06	2.34	1.81	0.86	1.38	2.22	1.23	1.84	0.00	-0.22	-1.11	1.12	1.57	1.35	1.11	0.93	0.33	0.18	0.17	0.14	0.11	0.10	0.09	0.07	0.04
EPS Diluted	15.45	17.64	19.46	15.98	9.17	7.24	5.59	5.09	4.92	4.71	3.48	3.21	3.46	2.53	2.01	2.25	1.72	0.84	1.36	2.17	1.20	1.73	0.00	-0.22	-1.10	1.08	1.41	1.22	0.99	0.82	0.29	0.17	0.16	0.13	0.10	0.09	0.09	0.07	0.04
Weighted Avg Shares Out	386.00M	392.00M	394.00M	396.00M	400.00M	402.00M	395.00M	394.80M	398.70M	398.20M	360.30M	363.80M	380.80M	403.30M	412.40M	418.20M	421.50M	196.10M	161.59M	163.13M	162.71M	168.33M	181.59M	164.14M	157.99M	162.41M	152.48M	141.53M	125.48M	110.80M	107.71M	91.04M	87.06M	70.60M	61.06M	58.72M	57.91M	58.74M	48.80M
Weighted Avg Shares Out (Dil)	388.00M	394.00M	397.00M	399.00M	403.00M	406.00M	398.00M	397.40M	401.90M	402.30M	365.80M	366.60M	384.80M	409.40M	423.03M	434.70M	443.70M	203.70M	165.33M	167.64M	170.73M	179.03M	185.02M	164.14M	158.22M	168.43M	169.79M	175.70M	158.10M	145.53M	107.71M	91.04M	87.06M	70.60M	61.06M	58.72M	57.91M	58.74M	48.80M

Thermo Fisher (TMO) to Open New NanoPort Facility in Taiwan

July 10, 2024zacks.com

Thermo Fisher (TMO) announces the opening of NanoPort, the company???s first electron microscopy demo center in Taiwan, strategically located in the region?

Thermo Fisher (TMO) Strategic Buyouts Aid Amid Macro Issues

July 9, 2024zacks.com

Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.

UK's competition regulator clears $3.1 bln Thermo Fisher Scientific-Olink deal

July 8, 2024reuters.com

UK's competition regulator said on Monday it has cleared U.S. medical equipment maker Thermo Fisher Scientific's $3.1 billion deal to buy Swedish biotech firm Olink Holding AB.

3 Biotech Stocks Turning DNA Dreams Into Dollars

July 5, 2024investorplace.com

When discussing biotechnology, many focus on medication based on biochemical compounds and their downstream effects. Yet several branches of medical genetics and therapeutics have begun to find novel ways to treat and prevent diseases through gene editing, protein manipulation and...

3 Nanotech Stocks That Could Make Your Grandchildren Rich

July 3, 2024investorplace.com

Advancements in semiconductor manufacturing, medical applications and materials science are projected to expand the nanotech market significantly in 2024. This backdrop forms the backdrop for my three nanotech stocks to buy.

Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs

July 3, 2024zacks.com

Thermo Fisher (TMO) has launched biobased solutions to help reduce the climate impact on the manufacturing of therapies.

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 24, 2024

July 2, 2024businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2024 before the market opens on Wednesday, July 24, 2024, and will hold a...